Diplomat Pharmacy, Inc. (DPLO) Forecasted to Post FY2017 Earnings of $0.86 Per Share
Diplomat Pharmacy, Inc. (NYSE:DPLO) – Leerink Swann boosted their FY2017 earnings per share estimates for Diplomat Pharmacy in a report released on Monday. Leerink Swann analyst D. Larsen now forecasts that the company will post earnings per share of $0.86 for the year, up from their previous estimate of $0.85. Leerink Swann has a “Outperform” rating and a $23.00 price objective on the stock. Leerink Swann also issued estimates for Diplomat Pharmacy’s Q4 2017 earnings at $0.18 EPS, Q1 2018 earnings at $0.22 EPS, Q2 2018 earnings at $0.22 EPS, Q3 2018 earnings at $0.22 EPS, Q4 2018 earnings at $0.23 EPS and FY2018 earnings at $0.90 EPS.
A number of other research analysts have also weighed in on the company. Robert W. Baird lowered Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $24.00 to $18.00 in a report on Thursday, November 16th. BidaskClub downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Mizuho raised their target price on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 7th. Needham & Company LLC raised their target price on Diplomat Pharmacy from $23.75 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Finally, Zacks Investment Research raised Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 target price for the company in a research report on Tuesday, October 10th. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $20.72.
Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Monday, November 6th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter last year, the firm posted $0.21 earnings per share. The firm’s revenue was down 4.8% on a year-over-year basis.
In other news, CFO Atul Kavthekar purchased 2,000 shares of the company’s stock in a transaction on Monday, November 20th. The stock was purchased at an average price of $15.00 per share, with a total value of $30,000.00. Following the completion of the purchase, the chief financial officer now directly owns 2,000 shares in the company, valued at approximately $30,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey G. Park purchased 3,000 shares of the company’s stock in a transaction on Monday, November 20th. The shares were purchased at an average cost of $15.46 per share, with a total value of $46,380.00. Following the purchase, the director now owns 7,640 shares of the company’s stock, valued at $118,114.40. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 15,000 shares of company stock valued at $228,780. 30.20% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio raised its position in Diplomat Pharmacy by 3,847.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 42,359 shares of the company’s stock valued at $877,000 after purchasing an additional 41,286 shares during the last quarter. Sterling Capital Management LLC bought a new position in Diplomat Pharmacy during the 3rd quarter valued at approximately $2,283,000. Piedmont Investment Advisors LLC bought a new position in Diplomat Pharmacy during the 3rd quarter valued at approximately $216,000. Continental Advisors LLC raised its position in Diplomat Pharmacy by 30.5% during the 3rd quarter. Continental Advisors LLC now owns 42,800 shares of the company’s stock valued at $886,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Diplomat Pharmacy during the 3rd quarter valued at approximately $8,226,000. 72.48% of the stock is owned by institutional investors.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.